Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: Nov 13, 2024
– Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient selection (p = 0.009) from ongoing ACR-368 registrational-intent Phase 2b endometrial cancer study presented at ESMO
Read more at globenewswire.com
